Related references
Note: Only part of the references are listed.New insights in gut-liver axis in wild-type murine imiquimod-induced lupus
Georges Maalouly et al.
LUPUS (2021)
Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease
Shogo Matsuda et al.
RHEUMATOLOGY (2020)
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2020)
Modeling pulmonary fibrosis through bleomycin delivered by osmotic minipump: a new histomorphometric method of evaluation
Francesca Ravanetti et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2020)
Beneficial role of simvastatin in experimental autoimmune myositis
G. Maalouly et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways
Qun Lv et al.
MOLECULAR MEDICINE (2020)
Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography
Francesca Ruscitti et al.
FRONTIERS IN PHARMACOLOGY (2020)
CXCR1 and CXCR2 Inhibition by Ladarixin Improves Neutrophil-Dependent Airway Inflammation in Mice
Matheus Silverio Mattos et al.
FRONTIERS IN IMMUNOLOGY (2020)
Interstitial Lung Disease in Polymyositis and Dermatomyositis
Kathryn Long et al.
CLINICS IN CHEST MEDICINE (2019)
Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3)
Chaochen Wu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Bridget F. Collins et al.
EUROPEAN RESPIRATORY REVIEW (2019)
Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis
Thomas Barba et al.
AUTOIMMUNITY REVIEWS (2019)
Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model
Jingwen Guo et al.
TOXICOLOGY LETTERS (2019)
Myositis-Related Interstitial Lung Diseases: Diagnostic Features, Treatment, and Complications
Courtney L. Shappley et al.
CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY (2019)
Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
Jin Jin et al.
RESPIRATORY RESEARCH (2019)
Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies
Christopher A. Mecoli et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy
Minoru Satoh et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2017)
Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis
Dana E. Mandel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies
Iago Pinal-Fernandez et al.
RHEUMATOLOGY (2017)
Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice
Francesca Ruscitti et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2017)
Narciclasine attenuates diet-induced obesity by promoting oxidative metabolism in skeletal muscle
Sofi G. Julien et al.
PLOS BIOLOGY (2017)
Skeletal Muscle Involvement in Antisynthetase Syndrome
Eri Noguchi et al.
JAMA NEUROLOGY (2017)
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Steven D. Nathan et al.
LANCET RESPIRATORY MEDICINE (2017)
Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis
Jun Tashiro et al.
FRONTIERS IN MEDICINE (2017)
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
miR-221 targets HMGA2 to inhibit bleomycin-induced pulmonary fibrosis by regulating TGF-β1/Smad3-induced EMT
Yi-Chun Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
TGF-β: the master regulator of fibrosis
Xiao-ming Meng et al.
NATURE REVIEWS NEPHROLOGY (2016)
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
Ting Li et al.
SCIENTIFIC REPORTS (2016)
Inflammatory Muscle Diseases
Marinos C. Dalakas
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients
Shigeaki Suzuki et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis
Li Zhang et al.
LABORATORY INVESTIGATION (2015)
Idiopathic inflammatory myopathies and the lung
Jean-Christophe Lega et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
Minoru Inomata et al.
RESPIRATORY RESEARCH (2014)
Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease
Takahisa Gono et al.
RHEUMATOLOGY (2014)
Interstitial lung disease
Katerina M. Antoniou et al.
EUROPEAN RESPIRATORY REVIEW (2014)
Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome
I. Marie et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2013)
Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome
Yasuhito Hamaguchi et al.
PLOS ONE (2013)
TGFβ signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment
Amber L. Degryse et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2011)
Pirfenidone for idiopathic pulmonary fibrosis
Demosthenes Bouros
LANCET (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies What Progress Has Been Made in the Past 35 Years?
Geoffrey R. Connors et al.
CHEST (2010)
Inflammatory muscle diseases: a critical review on pathogenesis and therapies
Marinos C. Dalakas
CURRENT OPINION IN PHARMACOLOGY (2010)
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Idiopathic pulmonary fibrosis and pirfenidone
H. R. Collard
EUROPEAN RESPIRATORY JOURNAL (2010)
Smad2 Protects against TGF-β/Smad3-Mediated Renal Fibrosis
Xiao Ming Meng et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Contribution of Epithelial-derived Fibroblasts to Bleomycin-induced Lung Fibrosis
Harikrishna Tanjore et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences
S. Bernatsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle
Andrew M. Bellinger et al.
NATURE MEDICINE (2009)
Standardized quantification of pulmonary fibrosis in histological samples
Ralf-Harto Huebner et al.
BIOTECHNIQUES (2008)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure
Ken W. Lee et al.
CIRCULATION (2006)
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge
Atsushi Hirano et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2006)
Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix
Kevin K. Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis
EH Kang et al.
RHEUMATOLOGY (2005)
Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model
HZ Liu et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2005)
Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation
MM Gueders et al.
JOURNAL OF IMMUNOLOGY (2005)
Smad-dependent and Smad-independent pathways in TGF-β family signalling
R Derynck et al.
NATURE (2003)
Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis
V Cottin et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
Inhibition of experimental acute pulmonary inflammation by pirfenidone
J Spond et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2003)
Interstitial lung disease in polymyositis and dermatomyositis
I Marie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation
DD Cataldo et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation
SN Iyer et al.
INFLAMMATION (2000)
Share Paper
